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Exacerbation of chronic liver disease 
due to hepatitis B surface antigen 
after delta infection 
SIR,—The report by Dr G Raimondo and others (12 March, p 845), in which the δ agent was 
implicated as the causal factor in three cases of fatal hepatitis, together with the fulminant cases 
reported by Smedile et al1 are of much concern since they show that, in Italy at least, δ acquired by 
a hepatitis B carrier is severely detrimental to the patient. 
 We have evidence, however, that the simultaneous acquisition of δ with hepatitis B does not 
cause an appreciable increase in severity in drug abusers with serologically acute hepatitis B. We 
have examined 212 drug abusers who developed hepatitis during a continuing outbreak of hepatitis 
B among drug abusers in Dublin2 and five long term drug abusing carriers of hepatitis B surface 
antigen (HBsAg) for δ antigenaemia, using enzyme immunoassay after detergent treatment, and for 
anti-δ, using enzyme immunoassay with serum as the δ antigen source; the specificity of our test 
has been confirmed on a sample by Dr Rizzetto (table). 
 There was no significant difference in the clinical findings between those with or without S 
antigenaemia, and there has been one fatal case in this group so far. Six of the 212 patients have 
become HBsAg carriers and four of these have anti-δ; the fatality occurred in one of these 14 
months after the acute episode. Additionally, five have been carriers for several years; we have not 
found S antigen retrospectively in stored sera from these five, but three have anti-δ. It is not known 
whether these three acquired their δ infections simultaneously with hepatitis B or subsequently. 
 It appears that in Ireland the acquisition of S and hepatitis B simultaneously is not usually 
associated with severe hepatitis, and this is similar to the experience in Sweden, where Moestrup et 
al (8 January, p 87) found only one fulminant case in 37 with acute hepatitis B and δ. The severe δ 
associated hepatitis reported from Italy seems to have occurred only in patients who were carriers of 
hepatitis B 
Results of tests for presence of δ markers, δ antigen, and anti- δ in 217 drug abusers 
Drug abusers tested No with δ 
markers 
No with δ antigen No with anti-δ Seropositive 
conversions 
212 with acute hepatitis B 72 (34%) 53 (25%) 19 (9%) 14 
5 HBsAg carriers 3 0 3 – 
and who acquired δ subsequently. The possibility of an ethnic (genetic) factor in δ pathogenicity 
must also be considered. 
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